|
Synonyms: AGN-150998 | MP0112
Compound class:
Peptide or derivative
Comment: Abicipar pegol is a VEGFA targeting protein conjugate generated using DARPin® technology [1,3]. The INN record for this construct describes it as a 'pegylated composite protein for clinical applications (CPCA)'. The amino acid sequence for the protein component is provided here. Structurally, the conjugate contains glycyl-seryl-ankyrin repeats (3-35, 36-68, 69-101, 102-123) with a short linker (127-134) and a cysteine di-sulphide bond (1-135), conjugated via a maleimide group linker (thioether bond to C135) to a single linear methoxy polyethylene glycol 20 (mPEG20). DARPins are protein therapeutics that are being developed as an alternative to antigen receptors (antibodies).
|
| No information available. |
Summary of Clinical Use  |
| Abicipar pegol is in Phase 2 clinical trial for neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), in which it is being compared to the currently used medication ranibizumab. Click here to link to ClinicalTrials.gov's listing for abicipar pegol trials. |
| Mechanism Of Action and Pharmacodynamic Effects |
| When delivered by intravitreal injection abicipar pegol binds to and inhibits the biologic activity of active forms of human vascular endothelial growth factor A in the eye, thus preventing the neo-vascularisation and vessel permeabiity changes associated with AMD and DME [2]. |
